Pharmamarketeer

EMA validates Gilead Sciences & Galapagos’ MAA for filgotinib to treat RA

Biopharmaceutical companies, Gilead Sciences and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults

Medhc-fases-banner
Advertentie(s)